Jean Paul Atallah

Jean Paul Atallah

Auto-generated profile, based on publicly available information

Jean Paul Atallah

Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
EMElias Moussaly
Elias Moussaly
BNBassel Nazha
Bassel Nazha
MZMazen Zaarour
Mazen Zaarour
JAJean Paul Atallah
Jean Paul Atallah
Primary Non-Hodgkin’s Lymphoma of the Spine: A Case Report and Literature Review

23 October 2017 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Open access
SGSassine Ghanem
Sassine Ghanem
GVGautam Kishore Valecha
Gautam Kishore Valecha
SHSami Hossri
Sami Hossri
UIUroosa Ibrahim
Uroosa Ibrahim
JAJean Paul Atallah
Jean Paul Atallah
(2017). Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. Expert Opinion on Investigational Drugs: Vol. 26, No. 12, pp. 1317-1319.

5 April 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
BABader Alshamsan
Bader Alshamsan
AGAhmed Mostafa Gad
Ahmed Mostafa Gad
MAMaaz Kamal Alata
Maaz Kamal Alata
MAMashari Alzahrani
Mashari Alzahrani
TETusneem A Elhassan
Tusneem A Elhassan
JAJean Paul Atallah
Jean Paul Atallah
Background. Numerous chemotherapeutic agents have antitumor activity in recurrent/metastatic (R/M) nasopharyngeal cancer (NPC). Evidence of capecitabine’s effectiveness as monotherapy is limited. Capecitabine tolerability in solid malignancies has ethnic and geographical variability. We investigated capecitabine’s tolerability and identified potential prognostic factors for clinical outcomes in R/M NPC. Methods. A consecutive retrospective cohort of patients who received capecitabine as the first recurrence, second- or third-line monotherapy for metastatic NPC (2011–2019) was reviewed concerning patient characteristics, pathological features, treatment outcomes, and toxicity. Results. Fifty-one patients were eligible (median age at diagnosis: 42 [35.5–52.5] years). Most patients (78.4%) tolerated a standard oral dose of 1,250 mg/m2 capecitabine (2 weeks on/1 week off) in a 3-week cycle. The objective response rate was 49%, and the disease control rate was 66.7%, with a median response duration of 6.2 months. Hand-foot syndrome (HFS) was associated with a higher objective response rate (odds ratio, 5.1 [95% confidence interval: 1.18–21.98]; ). The median follow-up duration was 17.8 (interquartile range: 7.8–30.4) months. The median (95% confidence interval) progression-free survival and overall survival were 6.6 (4.3–8.8) and 32.7 (25.9–39.5) months, respectively. HFS ( ), better performance status ( ), and absence of brain metastasis ( ) were associated with prolonged progression-free survival. Conclusion. Capecitabine monotherapy is effective and well-tolerated as a palliative treatment for R/M NPC. Despite the lower incidence of HFS in our patients, it remained a favorable prognostic factor for objective response and progression-free survival.

1 September 2016 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
MSMarc Saad
Marc Saad
EMElias Moussaly
Elias Moussaly
UIUroosa Ibrahim
Uroosa Ibrahim
JAJean Paul Atallah
Jean Paul Atallah
FFFrank Forte
Frank Forte
MOMarcel Odaimi
Marcel Odaimi